June 29 – July 2, 2024

European Academy of Neurology

July 1-4, 2023

European Academy of Neurology


European Academy of Neurology

EAN Presentations will be made available once embargo lifts on 28 June 2024, 18:30 EEST.

Ofatumumab – B Cell Therapy
Ofatumumab Efficacy & Safety

[EPR-097] Five-Year Efficacy Outcomes of Ofatumumab in Relapsing MS Patients: Insights From ALITHIOS Open-label Extension Study

Kappos L et. al

[EPR-303] Outcomes Of COVID-19 in Ofatumumab – treated RMS Patients: Data From the ALTHIOS Open label Extension Study

Wiendl H et. al

[EPR-302] Effect of Longer-term Ofatumumab Treatment on Disability Progression and Brain Volume Change

Wiendl H et. al

[EPO-642] Five-Year Safety of Ofatumumab in People Living With Relapsing Multiple Sclerosis

Sacca F et. al

[EPV-519] Ofatumumab, Interferón ß1 and Glatiramer Acetate As First-Line Treatment in Everyday Practice: The AIOLOS Study

Nelles G et. al
Remibrutinib – BTK inhibitor
Remibrutinib Safety

[EPO-146] Remibrutinib: A Novel BTKi in Development for MS With a Favorable Safety Profile in Various Autoimmune Disorders

Airas L et. al
Siponimod - S1P Receptor Modulator
Siponimod Efficacy & Safety

[EPO-331] Real World Insight into the Characteristics of Siponimod Treated SPMS Patients in Germany from the AMASIA Study

Hoffmann O et. al

[EPO-279] COVID-19 Outcomes and Vaccination to SARS-CoV-2 in Siponimod Treated Patients: Clinical Trial and Real-World Evidence

Schreiber H et. al

[EPO-330] AMASIA: Real World Insight into the Impact of Siponimod Treatment on Disease Progression of SPMS Patients in Germany

Hoffmann O et. al
Fingolimod - S1P Receptor Modulator
Fingolimod Efficacy

[EPR-301] PANGAEA 2.0 EVOLUTION: Clinical and Non-Clinical Parameters in the Early Assessment of SPMS Patients in Clinical Routine

Lassek C et. al
MS Treatment & Care
MS Management

[EPV-508] Quantitative MRI in the Routine Clinical care of MS patients: Final results from MAGNON

Hoffmann O et. al

[EPO-510] Multiple Sclerosis Treatment and Holistic Patient Care: Consensus of the Spanish Society of Neurology

Oreja-Guevara C. et. al
MLR ID - 289356

June 25-28, 2022 Congress list

Ofatumumab – B Cell Therapy
Ofatumumab & COVID-19 Vaccination

[EPR-169] COVID-19 Outcomes and Vaccination in Ofatumumab-treated RMS Patients: ALITHIOS Trial and Post-marketing Setting

Habek M, et al

[OPR-132] KYRIOS clinical trial: Tracking the immune response to SARS-CoV-2 mRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c.

Ziemssen T, et al
Ofatumumab Efficacy & Safety

[EPR-161] Longer-term Efficacy of Ofatumumab in Patients with Relapsing Multiple Sclerosis

Kappos L, et al

[OPR-130] Improvement in Cognitive Processing Speed With Ofatumumab in Patients With Relapsing Multiple Sclerosis

Benedict R, et al

[OPR-134] Longer-term Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis

Sacca F, et al
Siponimod - S1P Receptor Modulator
Siponimod & COVID-19 Vaccination

[OPR-133] AMA-VACC: Clinical trial assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod treated patients with secondary progressive multiple sclerosis

Ziemssen T, et al
Siponimod Efficacy and Safety

[EPR-056] Dynamics of Progression to Wheelchair in SPMS and Impact of Siponimod:Subgroup analyses from the EXPAND study

Vermersch P, et al

[OPR-120] Does Cognitive Impairment Predict Physical Disability Progression? Evidence from EXPAND, a Phase 3 Long-Term SPMS Study

Giovannoni G, et al

[EPR-032] The AMASIA study: Real World Insights on Siponimod Treated Patients with Secondary Progressive Multiple Sclerosis in Germany

Hoffman O, et al

[EPV-230] SWISSMASIA: Swiss Study of the Impact of Siponimod on SPMS Patients in a Long-term Non-interventional Study

Messner S, et al
Remibrutinib – BTK Inhibitor
Remibrutinib Efficacy & Safety

[EPR-009] REMODEL I and II Trials: Efficacy, Safety and Tolerability of Remibrutinib in Patients With Relapsing Multiple Sclerosis

Wiendl H, et al
MS Treatment & Care

[OPR-139] MAGNON Project: Implementation and Contribution of Lublin Criteria and quantitative MRI-Analysis for daily clinical routine of MS Patients

Hoffman O, et al

[EPR-159] Patient reported perspectives on disease burden and early signs of progression in multiple sclerosis in Germany (data collection MSPerspectives)

Bayas A, et al

[EPV-568] Characterization of the gait in patients with RRMS and SPMS measured by FeetMe®: Results of the MS Feet PRO study

Estruch C, et al
MLR ID - 221347

May 23–26, 2021, Virtual Meeting

Effect of Siponimod on MSWS-12 and MSIS-29 in Patients With SPMS From the EXPAND Study

ePresentation: EPR-226

A Functional Composite Endpoint to Characterize Disease progression in Patients with Active or non-Active Secondary Progressive Multiple Sclerosis

Oral presentation:OPR-157

A Patient-based Digital Tool to Detect Early Signs of Changes in MS Symptoms and Progression: Your MS Questionnaire


Efficacy of Ofatumumab on Microglia in Patients with Relapsing forms of Multiple Sclerosis: Study Design

ePresentation: EPR-225

Effectiveness and Tolerability of Ofatumumab Versus First-line Disease-modifying Treatments in Early Relapsing Multiple Sclerosis Patients: Phase 3b STHENOS Study Design

ePresentation: EPR-224

Patient Reported Outcomes used in Multiple Sclerosis Trials: Critical Assessment and Insights from People Living with MS

ePoster: EPO-462

Impact of Ofatumumab on Immune Responses Post-vaccination in RMS Patients: ALITHIOS Vaccination Sub-study Design

Oral presentation: OPR-207
MLR ID - 133484

June 19–22, 2020, Virtual Meeting

Evidence for Improved Myelination in Patients Treated with Siponimod: Results from the Phase 3 EXPAND Magnetic Resonance Imaging Substudy

ePresentation: EPR1147

Effect of Siponimod on Grey Matter Atrophy in Patients With Secondary Progressive Multiple Sclerosis: Subgroup Analyses From the EXPAND Study

ePresentation: EPR3098

Long term Efficacy of Siponimod Treatment for up to 5 Years in Patients with Secondary Progressive Multiple Sclerosis: Analysis of the EXPAND Extension Study

ePresentation: EPR2128

Siponimod Slows Physical Disability Progression and Decline in Cognitive Processing Speed in SPMS Patients with Active Disease: A Post Hoc Analysis of the EXPAND Study

ePresentation: EPR2118

Siponimod in the Central Nervous System: Translational Evidence on its Penetration and Distribution

ePresentation: EPR1152

Sphingosine 1-Phosphate Receptor Modulators as a Potential Treatment Option in COVID-19 Induced Acute Respiratory Distress Syndrome: Mechanistic Insights and Benefit Risk Assessment

eposter: C10

Effect of Ofatumumab on B cell Depletion and Efficacy Outcomes: Subgroup Analysis from the Pooled Phase 3 ASCLEPIOS I and II Trials

ePresentation: EPR3101

Effect of Ofatumumab Treatment on Disability Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis

Oral Presentation: O2034

Early Effect of Ofatumumab on B cell Counts and MRI Activity in Relapsing Multiple Sclerosis Patients: Results From the APLIOS Study

ePresentation: EPR3102

Effect of Subcutaneous Ofatumumab on Lymphocyte Subsets in Patients with RMS: Analysis from the APLIOS Study

ePoster: LB129

Ofatumumab vs Teriflunomide in Relapsing Multiple Sclerosis: Analysis of No Evidence of Disease Activity (NEDA-3) from ASCLEPIOS I and II Trials

ePoster: LB62

Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection Risk in Relapsing Multiple Sclerosis Patients from the Phase 3 ASCLEPIOS I and II Trials

ePoster: LB82

Understanding the Economic Burden of Secondary Progressive Multiple Sclerosis in Portugal

ePresentation: EPO2269

Transactivation of Endogenous Retroviruses by the Epstein-Barr Virus - Pathophysiologically Relevant key Mechanism of Multiple Sclerosis?

ePresentation: EPR3100

Click here for all published abstracts

click here
Cookie Settings